BIOSIMILAR THERAPEUTIC PEPTIDES MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-116077 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Biosimilar Therapeutic Peptides Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET
7.1 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA BIOSIMILAR THERAPEUTIC PEPTIDES MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Eli Lilly
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Sanofi
16.3 Takeda Pharmaceuticals
16.4 Teva Pharmaceuticals
16.5 Pfizer Inc.
16.6 Amgen Inc.
16.7 AstraZeneca PLC
16.8 GlaxoSmithKline (GSK)
16.9 Novartis AG
16.10 Novo Nordisk A/S
16.11 Ipsen S.A
16.12 Merck & Co. Inc.
16.13 F. Hoffmann-La Roche Ltd.
16.14 Bachem Holding AG
16.15 CordenPharma International
16.16 BioPartners
16.17 Hyperion Therapeutics
16.18 PeptiDream
16.19 Bachem Holding AG
16.20 Lonza Inc.
16.21 Bristol-Myers Squibb(BMS)
16.22 PolyPeptide Laboratories
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Route of AdministrationParenteral Route
Transdermal Route
Others
By Application
Cancer
Cardiovascular
Central Nervous Systems
Metabolic Disorders
Infection
Hematological Disorders
Gastrointestinal Disorders
Dermatology
Respiratory Disorders
Companies
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Teva Pharmaceuticals
Pfizer Inc.
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline (GSK)
Novartis AG
Novo Nordisk A/S
Ipsen S.A
Merck & Co. Inc.
F. Hoffmann-La Roche Ltd.
Bachem Holding AG
CordenPharma International
BioPartners
Hyperion Therapeutics
PeptiDream
Bachem Holding AG
Lonza Inc.
Bristol-Myers Squibb(BMS)
PolyPeptide Laboratories
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.